AVP and hypercalcemia disease: Hypercalcemia, which was present in 31% of our patients at baseline, is a hallmark of progressive myeloma and is known to impair renal function by decreasing the sensitivity of collecting ducts to antidiuretic hormone, reducing sodium reabsorption, increasing diuresis, and constricting afferent arterioles.